Pfizer Oncology Asia Chief Jorge Puente On Asia’s Role In Xalkori’s Success: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Jorge Puente, Pfizer’s regional president, Asia Pacific and Canada, Oncology BU, discusses the origins of the NSCLC therapy Xalkori, and how Asian clinical trials helped turbo-charge development of the oral, small molecule inhibitor of c-Met and ALK.